Clinical trials: Non-responders
Lupus Nephritis
A Study to Evaluate the Efficacy and Safety of Tacrolimus With Steroid in Korean Lupus Nephritis Patients
This study is to evaluate efficacy and safety of tacrolimus with steroid by observing remission rate at 24 weeks in lupus nephritis patients who are non-responders to steroid monotherapy.
- Trial name
- APPLE (NCT01316133)
- Testing
- tacrolimus
- Where
- 7 sites in South Korea
- Volunteers
- 37 people
- Sponsor
- Astellas Pharma Korea, Inc.
Congestive Heart Failure
SyncAV Post-Market Trial
The SyncAV Post-Market Trial is a prospective, randomized, multi-center trial performed to determine if cardiac resynchronization therapy (CRT) devices programmed with SyncAV ON improve long-term CRT response compared to devices…
- Trial name
- SyncAV (NCT04100148)
- Testing
- SyncAV programmed ON, Fixed AV delay
- Where
- 104 sites in United States, Austria and 23 more
- Volunteers
- 1,686 people
- Sponsor
- Abbott Medical Devices
Rheumatoid Arthritis
To Evaluate The Effect Of SAR153191 (REGN88) Added To Other RA Drugs In Patients With RA Who Are Not Responding To Or Intolerant Of Anti-TNF Therapy (SARIL-RA-TARGET)
Primary Objective: To demonstrate that sarilumab added to disease modifying anti-rheumatic drugs (DMARDs) were effective for: reduction of signs and symptoms at Week 24 and improvement of physical function at Week 12 in…
- Trial name
- NCT01709578
- Testing
- Sarilumab, hydroxychloroquine, methotrexate
- Where
- 196 sites in United States, Argentina and 28 more
- Volunteers
- 546 people
- Sponsor
- Sanofi
Chronic Hepatitis C
Thymosin Alpha-1 in Combination With Peg-Interferon Alfa- 2a and Ribavirin for the Therapy of Chronic Hepatitis C Nonresponsive to the Combination of IFN and Ribavirin.
The purpose of the study was to determine safety and efficacy of 48 weeks treatment with Thymosin alpha 1 (Talpha1) in combination with pegylated interferon (PEGIFN) alpha2a and ribavirin (RBV) in adult patients with chronic…
- Trial name
- NCT01178996
- Testing
- Thymosin alpha 1, Ribavirin, PEGinterferon alfa2a
- Where
- 9 sites in France, Germany and 3 more
- Volunteers
- 552 people
- Sponsor
- sigma-tau i.f.r. S.p.A.
Stable Coronary Artery Disease
A Study of the Antiplatelet Effects Comparing Ticagrelor (Ticag. - AZD6140) With Clopidogrel (Clop.) Responder and Non-responders
The purpose of this study is to see how Ticagrelor, a new oral reversible anti-platelet medication, affects platelets. Anti-platelet agents are medications that block the formation of blood clots by preventing the clumping of…
- Trial name
- RESPOND (NCT00642811)
- Testing
- Ticagrelor, Clopidogrel, Aspirin
- Where
- 10 sites in United States, Canada and 2 more
- Volunteers
- 98 people
- Sponsor
- AstraZeneca
Female Pattern Hair Loss, Androgenetic Alopecia
Minoxidil Dose Response Study in Females Identified Through IVD Testing as Non-Responders to 5% Topical Minoxidil
5% topical minoxidil is the maximum dosage approved by the US FDA for the treatment of female pattern hair loss. While topical minoxidil exhibits a good safety profile, the efficacy in the overall population is relatively low…
- Trial name
- NCT02486848
- Testing
- 5% Topical Minoxidil Solution, 15% Topical Minoxidil Solution
- Where
- Italy
- Sponsor
- Maja Kovacevic, MD
Hypertension
A Clinical Study to Evaluate the Safety and Efficacy of the Combination of Aliskiren and Amlodipine in Hypertensive Non Responders Patients
To evaluate the blood pressure lowering effect and safety of aliskiren 150 mg used in combination with amlodipine 5 mg in patients with essential hypertension not adequately responsive to amlodipine 5 mg.
- Trial name
- NCT00219076
- Testing
- aliskiren
- Where
- 2 sites in United States, Germany
- Volunteers
- 504 people
- Sponsor
- Novartis
Thyroid Eye Disease
An Open-label Study (OLE) for Non-responders of VRDN-001-101 and VRDN-001-301
The investigational drug, VRDN-001, is a monoclonal antibody that inhibits the activity of a cell surface receptor called insulin-like growth factor-1 receptor (IGF-1R).
- Trial name
- OLE (NCT06179875)
- Testing
- Veligrotug
- Where
- 45 sites in United States, France and 6 more
- Volunteers
- 139 people
- Sponsor
- Viridian Therapeutics, Inc.
Hepatitis C
A Study to Evaluate the Efficacy and Safety of Boceprevir Added to Standard of Care Therapy in Previously Treated Participants With Chronic Hepatitis C Genotype 1 and Cirrhosis (MK-3034-105)
This study is being done to find out if the addition of boceprevir to standard of care (SOC) treatment with peginterferon alfa-2b (PegIFN-2b) + ribavirin (RBV) is effective for participants with chronic hepatitis C (CHC) genotype…
- Trial name
- NCT01756079
- Testing
- boceprevir, PegIFN-2b, RBV
- Volunteers
- 58 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis B
Study to Evaluate Induction of HBV Virus Neutralizing Antibodies Using VVX001
The Study will evaluate the effects of VVX001, a novel vaccine for hepatitis B, to elicit a robust protective IgG immune response in vaccine naive subjects in subjects who failed to demonstrate seroconversion after treatment with…
- Trial name
- NCT03625934
- Testing
- VVX001
- Where
- 2 sites in Austria
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Viravaxx AG
Rheumatoid Arthritis
An Observational Study of MabThera/Rituxan (Rituximab) and Alternative TNF-Inhibitors in Patients With Rheumatoid Arthritis and an Inadequate Response to a Single Previous TNF-Inhibitor
This multicenter, prospective, observational study will assess the efficacy of MabThera/Rituxan (rituximab) and alternative TNF-inhibitors in patients with rheumatoid arthritis who are non-responders or intolerant to a single…
- Trial name
- NCT01557348
- Where
- 215 sites in Canada, Colombia and 10 more
- Volunteers
- 1,239 people
- Sponsor
- Hoffmann-La Roche
Diabetes Mellitus, Type 2
RF Vapor Ablation Retreatment of Duodenal Mucosa in Non-responders With Type-2 Diabetes Mellitus
The purpose of this study is to test the hypothesis that re-treatment of the duodenal mucosa with RF vapor ablation will result in improvement in glycemic parameters, without complications (bleeding/ stricture / perforation)…
- Trial name
- NCT06724822
- Testing
- RF Vapor Ablation
- Where
- Chile
- Volunteers
- 12 people
- Sponsor
- Aqua Medical, Inc.
Hepatitis C
Efficacy and Safety of Adding Alisporivir (DEB025) to Peginterferon (IFN) Alfa-2a (Peg-IFN Alfa-2a) and Ribavirin in Chronic HCV Genotype 1 Patients Who Relapsed or Did Not Respond to Previous Treatment
The study is to investigate whether participants with hepatitis C virus (HCV) genotype 1 who have a history of non-response/relapse to peginterferon alfa-2a (PEG) and ribavirin (RBV) may benefit from treatment with triple therapy…
- Trial name
- NCT01183169
- Testing
- Alisporivir, Peginterferon alfa-2a, Ribavirin
- Where
- 75 sites in United States, Australia and 12 more
- Volunteers
- 459 people
- Sponsor
- Debiopharm International SA
Carcinoma, Hepatocellular
Pegylated Alfa-2b Interferon Therapy of Patients With Hepatitis C-related Cirrhosis and High Liver Cell Proliferation (P02733/MK-4031-085)
This study aims to compare the role of peginterferon α-2b (50 μg/week) vs. control (no treatment) in the prevention of hepatocellular carcinoma, in adult patients with cirrhosis and initial signs of portal hypertension who did…
- Trial name
- NCT00759109
- Testing
- Peginterferon alfa-2b, Observation (no treatment)
- Volunteers
- 150 people
- Sponsor
- Merck Sharp & Dohme LLC
HIV Infections
A Study to Evaluate JL18008 in Subject With HIV Immunological Non-Responders
The Phase Ib clinical trial is an add-on study based on combination antiretroviral therapy (cART). It adopts a multicenter, randomized, double-blind, placebo-controlled, multiple-dose design to evaluate the safety and efficacy of…
- Trial name
- JL18008 (NCT07579741)
- Testing
- JL18008 20 μg/kg, JL18008 40 μg/kg, JL18008 70 μg/kg
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Jecho Biopharmaceuticals Co., Ltd.
Hepatitis C, Chronic
An Extension Study to Evaluate the Safety and Efficacy of Celgosivir and Peginterferon Alfa-2b, With or Without Ribavirin, in Patients With Chronic Hepatitis C Genotype 1 Infection
This is an extension study of HCV-05-002. The objective of this study is to evaluate the safety and efficacy of celgosivir plus peginterferon alfa-2b, with or without ribavirin, for an additional 36 weeks in patients with chronic…
- Trial name
- NCT00292084
- Testing
- Celgosivir
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- BioWest Therapeutics Inc
PTSD
Residential Retreat for Veterans and First-responders
The purpose of this study is to determine the potential efficacy and feasibility of a residential retreat program to address PTSD symptoms in Veterans and First-responders
- Trial name
- NCT05311696
- Testing
- psychoeducation
- Where
- Canada
- Volunteers
- 70 people
- Sponsor
- Valhalla Project Niagara
Chronic Hepatitis C
CIFN and IFN γ-1b With or Without Ribavirin for Treatment of Chronic Hepatitis C (Nonresponders)
To evaluate the safety and tolerability of two different doses of Consensus Interferon-Alpha and Interferon Gamma-1b with or without ribavirin in patients with chronic hepatitis C who are non-responders to PEG-IFN-a 2a or…
- Trial name
- NCT00084279
- Testing
- Consensus Interferon-Alpha, Interferon Gamma-1b, Ribavirin
- Where
- United States
- Volunteers
- 81 people
- Sponsor
- InterMune
Hepatitis C, Chronic
Vaniprevir Plus PegIntron®/Ribavirin in Japanese Participants With Chronic Hepatitis C Who Are Non-responders to Previous Treatment (MK-7009-045)
The purpose of this study is to evaluate the safety, tolerability, and efficacy of vaniprevir (300 mg twice daily) given in combination with pegylated interferon alfa-2b (peg-IFN) and ribavirin (RBV) in Japanese participants with…
- Trial name
- NCT01405560
- Testing
- Vaniprevir, peg-IFN, ribavirin
- Volunteers
- 42 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Hepatitis C
Long-Term Extension Study of Miravirsen Among Participants With Genotype 1 Chronic Hepatitis C (CHC) Who Have Not Responded to Pegylated-Interferon Alpha Plus Ribavirin
Genotype 1 CHC participants from Study SPC3649-207 with null response to prior pegylated-interferon alpha plus ribavirin will be enrolled into this 36-month extension study, designed to evaluate the long-term safety and efficacy…
- Trial name
- NCT02508090
- Where
- Puerto Rico
- Volunteers
- 10 people
- Sponsor
- Hoffmann-La Roche